CSRxP issued the following statement in response to the U.S. Department of Health and Human Services’ (HHS) announcement on direct-to-consumer (DTC) television advertisements: “Today, the Trump Administration made real progress toward ensuring consumers have the information they need to make the health care decisions that are best for them. Consumers have the right to know how much medicines […]
Defeat For Price-Gouging Drug Manufacturers; Victory For Taxpayers & Patients For Immediate Release: Contact: Lauren Blair (201) 213-5004 [email protected] The Campaign for Sustainable Rx Pricing released the following statement after House and Senate Committee leaders introduced the Opioid Crisis Response Act of 2018 without changes to the Medicare Part D program, which would have […]
Washington, D.C. – Today the Campaign for Sustainable Rx Pricing, joined by several groups committed to lowering drug prices, sent a letter to Senate Majority Leader Mitch McConnell, Senate Minority Leader Chuck Schumer, House Speaker Paul Ryan and House Minority Leader Nancy Pelosi, urging them not to include a multi-billion dollar bailout for Big Pharma […]
“Only Big Pharma would use bipartisan opioid legislation as another opportunity to make money off the very crisis they themselves created. The focus of this effort is no longer about helping communities affected by the opioid epidemic, it’s about further enriching Big Pharma on the backs of seniors, while hoping no one notices. For all the […]
CSRxP-Supported Policy Enables HHS To Require Drug Price Disclosure In Direct-To-Consumer Advertising Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) sent a letter urging members of the U.S. House Committee on Appropriations to maintain a provision in the Senate-passed appropriations “minibus” package that would provide funding to enable the U.S. Department of Health […]
Legislation Includes CSRxP-Supported Amendment Enabling HHS To Require Disclosure of Drug Prices in Direct-to-Consumer Advertising The Campaign for Sustainable Rx Pricing issued the following statement after the Senate took action to enhance drug pricing transparency by passing legislation that included a CSRxP-supported amendment – introduced by Senator Dick Durbin (D-IL) and Senator Chuck Grassley (R-IA) – […]
CSRxP spokesman Will Holley released the following statement in response to today’s report that Celgene will once again raise the price of Revlimid: “Today’s announcement that Celgene is yet again raising the price of Revlimid demonstrates very clearly the failures of the prescription drug market in the United States. Over the last 18 months, Celgene […]
CSRxP spokesman Will Holley released the following statement in response to Secretary Azar’s testimony in front of the Senate Finance Committee today: “The Administration’s focus on out-of-control list and launch prices is a step in the right direction towards our shared goal of more-affordable prescription drugs. In particular, we were encouraged to hear Secretary Azar’s response […]
The Campaign for Sustainable Rx Pricing today released testimony for the record submitted to the Senate Finance Committee in advance of tomorrow’s hearing, “Prescription Drug Affordability and Innovation: Addressing Challenges in Today’s Market.” The testimony applauds the Trump Administration recently-released Blueprint to Lower Drug Prices as a welcome step in the right direction towards reining-in […]
“We applaud the members of the Senate Judiciary Committee for voting the CREATES Act out of committee and advancing this bipartisan legislation one step closer to becoming law. “The CREATES Act will put an end to anticompetitive practices used by some drug manufacturers to thwart generic competition and artificially keep drug prices high. It is […]